Signature Wealth Management Partners LLC Buys 232,426 Shares of Amneal Pharmaceuticals, Inc. $AMRX

Signature Wealth Management Partners LLC bought a new position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) in the 3rd quarter, HoldingsChannel.com reports. The fund bought 232,426 shares of the company’s stock, valued at approximately $4,681,000. Amneal Pharmaceuticals comprises about 2.0% of Signature Wealth Management Partners LLC’s holdings, making the stock its 12th biggest position.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Diversify Advisory Services LLC lifted its stake in shares of Amneal Pharmaceuticals by 572.1% in the 3rd quarter. Diversify Advisory Services LLC now owns 119,275 shares of the company’s stock valued at $2,296,000 after purchasing an additional 101,529 shares during the last quarter. Quantum Financial Partners LLC increased its position in shares of Amneal Pharmaceuticals by 19.4% during the 3rd quarter. Quantum Financial Partners LLC now owns 12,300 shares of the company’s stock worth $248,000 after purchasing an additional 2,000 shares during the last quarter. Fortitude Family Office LLC increased its position in shares of Amneal Pharmaceuticals by 100.9% during the 3rd quarter. Fortitude Family Office LLC now owns 1,607 shares of the company’s stock worth $32,000 after purchasing an additional 807 shares during the last quarter. GK Wealth Management LLC purchased a new stake in Amneal Pharmaceuticals in the 3rd quarter valued at about $103,000. Finally, Balefire LLC purchased a new stake in Amneal Pharmaceuticals in the 3rd quarter valued at about $217,000. Hedge funds and other institutional investors own 31.82% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the stock. Wall Street Zen raised shares of Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Sunday, July 12th. Leerink Partners assumed coverage on shares of Amneal Pharmaceuticals in a research report on Wednesday, September 9th. They set an “outperform” rating and a $23.00 price target for the company. UBS Group reiterated a “buy” rating on shares of Amneal Pharmaceuticals in a research report on Thursday, October 1st. Barclays boosted their price target on shares of Amneal Pharmaceuticals from $16.00 to $20.00 and gave the company an “overweight” rating in a research note on Thursday, September 17th. Finally, The Goldman Sachs Group restated a “buy” rating and issued a $21.00 price objective on shares of Amneal Pharmaceuticals in a report on Friday, July 31st. Nine investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $21.00.

Insider Buying and Selling

In other Amneal Pharmaceuticals news, EVP Jason B. Daly sold 210,000 shares of Amneal Pharmaceuticals stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $17.40, for a total value of $3,654,000.00. Following the completion of the transaction, the executive vice president directly owned 35,171 shares of the company’s stock, valued at $611,975.40. The trade was a 85.65% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director John Kiely sold 50,000 shares of Amneal Pharmaceuticals stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $17.64, for a total value of $882,000.00. Following the completion of the transaction, the director directly owned 210,252 shares of the company’s stock, valued at approximately $3,708,845.28. This represents a 19.21% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 413,016 shares of company stock valued at $7,216,567. Corporate insiders own 17.30% of the company’s stock.

Amneal Pharmaceuticals Stock Up 1.8%

NASDAQ:AMRX opened at $20.20 on Thursday. Amneal Pharmaceuticals, Inc. has a 52 week low of $9.99 and a 52 week high of $21.17. The stock’s fifty day moving average is $18.68 and its two-hundred day moving average is $16.36. The stock has a market capitalization of $6.45 billion, a price-to-earnings ratio of 41.22, a price-to-earnings-growth ratio of 2.33 and a beta of 1.22. The company has a quick ratio of 1.44, a current ratio of 2.20 and a debt-to-equity ratio of 77.65.

Amneal Pharmaceuticals (NASDAQ:AMRX) last issued its quarterly earnings data on Thursday, July 30th. The company reported $0.30 earnings per share for the quarter, beating analysts’ consensus estimates of $0.24 by $0.06. Amneal Pharmaceuticals had a negative return on equity of 584.46% and a net margin of 5.05%. The business had revenue of $796.20 million during the quarter. Amneal Pharmaceuticals has set its FY 2026 guidance at 0.960-1.060 EPS. Research analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.95 EPS for the current year.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and commercializes a broad portfolio of generic and specialty medicines. Its products include oral, injectable and inhaled medications, as well as complex dosage forms and other products designed to address areas where manufacturing or formulation requirements can be more challenging.

The company’s generics business offers medicines across a range of therapeutic categories, including central nervous system, cardiovascular, gastrointestinal, anti-infective and other treatments.